Actively Recruiting
Randomized, Placebo-Controlled Study of Bilateral Rectus Sheath Catheters for Pain Relief After Midline Laparotomy
Led by Asklepios Kliniken Hamburg GmbH · Updated on 2026-10-28
40
Participants Needed
1
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the use of rectus sheath catheters RSC to provide pain relief after midline laparotomy surgeries. This trial evaluates whether local anesthetics delivered via RSC add significant pain control benefits within a multimodal pain management approach. The study compares the effects of an active anesthetic versus a placebo on pain scores, quality of recovery, and opioid use in the first 72 hours after surgery. Participants are randomly assigned to receive either ropivacaine 0.2% or saline 0.9% through bilateral rectus sheath catheters placed during surgery after closing the laparotomy incision. The catheters deliver doses every 8 hours, with ropivacaine dosed at 2x30ml every 8 hours for a total daily dose of 360 mg. The placebo group receives the same volume and timing of saline. Standard anesthesia and multimodal pain medications, including dexamethasone, metamizole or parecoxib, and paracetamol, are also administered. During the study, participants are monitored closely in the recovery room or intensive care unit, with ongoing pain assessments using numeric rating scales up to 72 hours after surgery. Opioid consumption is tracked daily, and quality of recovery scores are collected. Safety monitoring includes recording postoperative complications up to 14 days post-randomization. Participants receive routine postoperative care alongside study interventions and are observed for patient satisfaction and analgesic effectiveness.
CONDITIONS
Brief Title
Rectus Sheath Catheters Following Midline Laparotomy
Research Team
R
Ronald Seidel, Dr.med.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here